FAQ: Soligenix Updates Medical Advisory Board for HyBryte™ Phase 3 CTCL Development
Summary
Soligenix Inc. has updated its U.S. Medical Advisory Board to advance Phase 3 development of HyBryte™, a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), reinforcing the company's commitment to bringing this treatment to patients worldwide.
What is the main announcement from Soligenix?
Soligenix has updated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte™ (synthetic hypericin), a photodynamic therapy treatment.
What is HyBryte™ and what condition does it treat?
HyBryte™ (SGX301 or synthetic hypericin sodium) is a novel photodynamic therapy that utilizes safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease.
Why is this Medical Advisory Board update significant?
The addition of new key opinion leaders reinforces the program’s clinical depth and demonstrates Soligenix’s commitment to advancing regulatory and commercialization activities for HyBryte™ worldwide.
What stage of development is HyBryte™ currently in?
HyBryte™ is in Phase 3 development for CTCL, with successful completion of the second Phase 3 study, and the company is seeking regulatory approvals to support potential commercialization.
Who is leading Soligenix and what did they say about this update?
President and CEO Christopher J. Schaber, PhD stated that the addition of new key opinion leaders reinforces the program’s clinical depth and the company’s commitment to bringing HyBryte™ to CTCL patients worldwide.
What other conditions is Soligenix developing treatments for?
Soligenix is developing synthetic hypericin (SGX302) for psoriasis, dusquetide (SGX942) for inflammatory diseases including oral mucositis, SGX945 for Behcet’s Disease, and vaccine programs for ricin toxin, filoviruses, and COVID-19.
Where can investors find more information about Soligenix?
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
What is Soligenix’s focus as a company?
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, with two main business segments: Specialized BioTherapeutics and Public Health Solutions.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 251920